Vymo Launches Manager Experience (MeX) to Drive Preemptive Interventions and Improve Sales Outcomes by Over 200%

Vymo’s Manager Experience (MeX) helps managers intervene in-the-moment to coach sales teams proactively and is available as an upgrade on the Vymo Personal Sales Assistant app


BANGALORE, India and SINGAPORE, June 3, 2020 /PRNewswire/ — Vymo, a pioneer in Sales Automation and Intelligence solutions for distributed sales teams has launched the Vymo Manager Experience (MeX), an upgrade on its Personal Sales Assistant app, focused on enabling managers to drive proactive interventions.

Vymo MeX Experience
Vymo MeX Experience

Currently being piloted with some of the largest financial services companies in the World, MeX has enabled sales teams to sell 2x more policies and collect 320% more premiums. The solution has also reduced turnaround time for customers by 70-75%.

Combining Vymo’s cutting edge features on sales activity capture and nudge intelligence, Vymo Manager Experience (MeX) enables:

  • A unified view of sales teams’ KPIs with activities and goals,
  • Comprehensive customer account and engagement planning, and
  • In-the-moment coaching interventions through exception alerts

Speaking on the launch, Harish Vaidyanathan, SVP – Product, Vymo, said, “Sales and CRM systems have generally been used as inspection tools by managers and supervisors. As a result, salespeople have always been skeptical of using new technology. Vymo has always put the sales end-user at the center of the experience, which is why we have a phenomenal daily user adoption of over 85%. Manager experience helps managers move beyond monitoring activities to actually helping their teams meet outcomes proactively. Judging by the successful pilots we have had, we are excited to see this being adopted across the industry.”

Vymo is hosting an expert insights session on Friday, 11:00 AM IST / 01:30 PM SGT to elaborate on how Vymo MEX helped managers empower their teams to improve performance metrics. The live discussion will be led by Harish Vaidyanathan, SVP – Product, Vymo. Click here to register – https://getvymo.com/mex

About Vymo
Vymo (getvymo.com) is an intelligent Personal Sales Assistant. Vymo has over 100,000 users in 60+ large enterprises such as Axa, Allianz, HDFC Bank, VPBank, AIA and Generali. Vymo is recognized by Gartner as a Cool Vendor and funded by Emergence Capital and Sequoia Capital.

Related Links
Website – https://www.getvymo.com
Register for MeX insights – https://www.getvymo.com/mex
Schedule a demo – https://www.getvymo.com/demo
Download Logo – Link

Logo – https://mma.prnewswire.com/media/1026997/Vymo_Logo.jpg
Photo – https://mma.prnewswire.com/media/1176084/Vymo_MeX_Experience.jpg  

Media Contact
Gunjan Saha

Related Links :


Novena Global Lifecare establishes new foray into Personal Care Devices with DOCO

Novena Global Lifecare expands into personal care device market with up to S$20 million investment of Chinese startup, DOCO

  • Amidst challenging times, Novena Global Lifecare has announced an up to S$20 million strategic investment into DOCO, a technology and design innovation oriented beauty personal care brand in China
  • Novena Global Lifecare (“NGL”) aims to be on the forefront to create an ecosystem of services and products, enabled by Internet of Things and Robotics
  • Under Novena Global Lifecare group of companies’, Novena Life Sciences, the venture with DOCO looks to ship an expected over 1,000,000 units in the next eighteen months globally

SINGAPORE, June 3, 2020 /PRNewswire/ — Novena Global Lifecare (the “Company”), one of the world’s largest integrated medical healthcare and specialty clinics with over 250 locations in 20 cities has increased its foothold further with a strategic investment of up to S$20 million strategic investment into DOCO, a technology and design innovation oriented beauty personal care brand in China.

Novena Global Lifecare establishes new foray into Personal Care Devices with DOCO
Novena Global Lifecare establishes new foray into Personal Care Devices with DOCO

Founded in 2018, DOCO has successively launched products such as Smart Sonic facial cleanser tool, beauty instruments and beauty mirrors. Its first product “smart sonic facial cleanser” with its compact outlook is able to detect skin condition to calibrate itself to user’s needs.

The product has won iF Design award in Germany for consecutively in 2019 and 2020. Launched last year by Xiaomi and is now ranked top in the beauty category on Xiaomi E-platform and one of the best sellers in skin care category on top beauty platforms such as JD.com, T mall, Sephora and Afiona.com. It is also sold in over 200 beauty stores.


Singapore-owned Novena Global Lifecare under its subsidiary, Novena Life Sciences, melds its strength and expertise with DOCO to break further into the burgeoning beauty device market. In 2018, the global beauty device market was valued at USD 39.1 billion in 2018 and is expected to reach USD 107.2 billion by 2024. The beauty devices market is poised to grow at an annual growth rate of 18.4% during the forecast period (2019-2024).

To date, Novena Life Sciences boosts over 100 points in beauty, aesthetics and medi-spas in China and will pave the way for assessing this vast market. In turn, DOCO will serve to complement the company’s service offerings with home product extensions – thereby capitalising on the uptake in demand for home use beauty solutions during the global pandemic.

Furthermore, Novena Global Lifecare will provide medical insights alongside DOCO’s commercial product development expertise to accelerate the launch of professional and tech-driven products in the beauty equipment and personal care tools markets for China and the Asia-Pacific region. Its deep knowledge of medical procedures and background in life science research also empowers the implementation of safe and beneficial product development, and propel the creation of bespoke beauty solutions.

Nelson Loh, Co-founder of Novena Global Lifecare says, “The new venture with DOCO brings an exhilarating time for Novena Global Lifecare. We invest in the potential in DOCO as it is led by Xiao Zongwei, its founder alongside his team, whose experiences in consumer electronics product design and development range from Xiaomi, Longqi (Meitu app), Tencent and Baidu.

DOCO has also shown its success in recent launches such as the likes of T-mall in China, in addition to expanding globally in US, Canada, Europe and EU countries with an expected forecast to ship over a million units in the next eighteen months.

The future of the beauty industry will be a multi-brand matrix, and the service scene will not be limited to in-store. As user demand increases, the consumer touchpoints from home maintenance to in-store care to cosmetic-medical industry, all of which has broad prospects and opportunities. This is seen now as beauty and personal care products market continually sees with double digit growth year on year. “

Plans are already ahead with DOCO to develop professional high-end home beauty devices. Novena Global Lifecare believes that compared with large medical beauty equipment, beauty appliances can more easily meet the daily needs of users and achieve rapid iteration. DOCO has also cooperated with Stark, a brand of Weixing Medical Technology, to jointly launch hair straighteners, hair dryers, hair clippers, razors and other hair care products and has launched its first collaboration in Mid-May.


Terence Loh, Co-founder and CEO of Novena Global Lifecare adds, “The venture aligns our vision to redefine the new parameters of change, using technology to evolve Novena Global Lifecare to be a provider in the Internet of Things (IoT) and Robotics but also proves to be an fitting extension to both our medical healthcare and aesthetics business channels as we strive to create a seamless and integrated network of services & products for our customers.

The strategic investment cooperation with DOCO is also an important for the group to improve the R&D capabilities. DOCO has accumulated material in hardware research and development, and channel expansion. Novena Global lifecare has more than 10 million users and has accumulated a large amount of data on skin, hair and care needs, with accurate user demand models. Through the integration of resources, the two parties will aims to propel new product innovations and plan to extend into areas such as professional beauty care, and even into home-use of medical and aesthetic technology based on R&D capabilities and patented technologies.”

The convergence of technology, lifestyle and beauty is even more apparent today as the foreseeable low touch economy continues, Novena Global Lifecare aims to drive smart design to provide precision and empower consumers to create their own experiences and products though technology.

DOCO, as a new generation of young brands in China will hope to grow with the strength of the Chinese market and its world-class product design and scientific research capabilities. With the addition to the Novena Global Lifecare network, there is high hopes that DOCO will win a place in the beauty and personal care market in China and the Asia-Pacific region.”

About Novena Global Lifecare

Novena Global Lifecare (NGL) is one of the largest integrated medical healthcare and aesthetic groups regionally with presence in Singapore, mainland China, Hong Kong, South Korea, Taiwan, Indonesia, India and Malaysia.

Founded in 2010 by former investment bankers and cousins Terence and Nelson Loh, the group’s network is now in 250 locations in over 20 cities and drives a multi-million revenue portfolio that provides lifecare management solutions from health screenings, day surgery centres and aesthetics clinics tailored to Asian demographics to help customers in their journey of well-being across their life stages.

NGL has established a track record of more than 8 million procedures performed worldwide and over 2 million patients in its Pan Asian patient database. Founded in 2016, NGL is the first medical aesthetics group in the world to integrate in-house medical equipment manufacturing, CRM data analytics, and research and development and sells its line of skincare products in some 1,000 points of sale in the world. NGL’s subsidiaries include Novena Life Sciences is the largest enterprise health screening provider in Taiwan which carries out corporate health screenings.

With the recent pandemic, Novena Global Lifecare established a new business unit to focus on PPE medical supplies and has been appointed by the various Government’s Coronavirus task force to support with both sourcing and compliance management across a number of medical PPE supplies including invasive ventilators, PPE masks and Covid-19 Test kits.  

Visit www.novenagloballifecare.com for more details.

Photo – https://photos.prnasia.com/prnh/20200601/2818235-1?lang=0


Related Links :


Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study

SUZHOU, China, June 3, 2020 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces the preliminary results of a Phase 1 clinical study (NCT03545971) of the recombinant fully human anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody (IBI310) in the form of online publication at the 56th American Society of Clinical Oncology (ASCO) Annual Meeting. (Online publication, Abstract # 302489)

The NCT03545971 study is an open-label study and was consisted of two parts, namely Phase 1a study and Phase 1b study, which were designed to evaluate the tolerability, safety and anti-tumor activity of IBI310 and its combination with TYVYT® (sintilimab injection) in the treatment of subjects with advanced malignant tumors, respectively. In the Phase 1a study, subjects with advanced solid tumors who have progressed from standard treatment were dosed with IBI310; while in the Phase 1b study, subjects with advanced melanoma were treated with IBI310 in combination with TYVYT® (sintilimab injection). The main clinical data includes:

  • As of November 12, 2019, a total of 10 subjects were enrolled in Phase 1a study and 17 subjects were enrolled in Phase 1b study. There were no dose limiting toxicities (DLTs) in both phases, and the dose expansion in Phase 1b is currently ongoing. The most common treatment related adverse event (TRAE) was pruritus in both Phase 1a and Phase 1b studies, and no Grade 3 or higher adverse events occurred in Phase 1a and only one subject in Phase 1b experienced a grade 3 or higher TRAE (AST increased). There were no TEAE caused death.
  • In Phase 1b study, three subjects in the 3mg combination dose group had at least one tumor assessment and one of these subjects had objective response.

Professor Jun Guo, Vice President of Peking University Cancer Hospital and Director of the Department of Melanoma Medicine of Renal Cancer, said: “In recent years, several breakthroughs achieved in melanoma have brought more treatment methods for patients with melanoma. The 1-year survival rate of patients with advanced melanoma has been prolonged from 25% ~ 35% in the 1990s to 75% by today, and immunotherapy is one of the most critical breakthroughs for this improvement. The results of Checkmate-067 study showed that double immunotherapy for first-line treatment of advanced melanoma can significantly improve the prognosis compared to single immunotherapy. The preliminary results of NCT03545971 study show that IBI310 have acceptable safety profile and preliminary efficacy. We hope to see more positive data in the next studies.”

Dr. Hui Zhou, Vice President of Medical Science and Strategic Oncology of Innovent, said: “CTLA-4 is an important immunosuppressive receptor, and there are a number of CTLA-4 related clinical studies on-going both in domestic and abroad, while currently only one has been approved. IBI310 is the CTLA-4 monoclonal antibody of fastest progress in China. The preliminary clinical results of IBI310 in combination with sintilimab show acceptable safety and anti-tumor activity, suggesting a synergistic enhancement effect. Currently, Phase 2/3 clinical studies of IBI310 in combination with sintilimab are on-going in multi tumors. We hope to evaluate the clinical results of IBI310 in combination with sintilimab and bring this therapy to more patients in need as soon as possible. “

About IBI310 (Anti-CTLA-4 Monoclonal Antibody)

IBI310 is a fully human monoclonal antibody blocking Cytotoxic T Lymphocyte-associated Antigen-4 (CTLA-4). CTLA-4 inhibits the immune escape of tumor cells and improves the body’s own immune response against tumor cells by up-regulating the anti-tumor immune response mediated by human effector T cells and weakening the immunosuppressive activity mediated by regulatory T cells, so as to achieve the purpose of treating a variety of tumors.

About Innovent

Inspired by the spirit of “Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of cancer, metabolic, autoimmune and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Since its inception, Innovent has developed a fully integrated multifunctional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 17 in clinical development, five in Phase 3 or pivotal clinical trials, four under NDA reviews by the NMPA (three under priority review status), while TYVYT® (sintilimab injection), officially approved for marketing in China in 2018, has been the only PD-1 inhibitor included in the NRDL, since 2019.

Innovent has built an international team of advanced talents in high-end biological drug development and commercialization, including many overseas experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners. Innovent strives to work with all relevant parties to help advance China’s biopharmaceutical industry, improve drug availability to ordinary people and enhance the quality of the patients’ lives. For more information, please visit:www.innoventbio.com.

Related Links :


Atlantic Nickel Resource and Operational Update for Santa Rita

LONDON, June 3, 2020 /PRNewswire/ —


  • Decisive action taken to safeguard employees and local communities during the COVID-19 pandemic
  • Santa Rita remains fully operational with minimal disruptions to supply chain
  • First quartile C1 cost performance of US$3.29/lb Ni achieved in Q1 2020, net of by-products
  • Second and third shipments complete; more than 30,000 tonnes of nickel concentrate produced to date
  • Updated Mineral Resource (underground) increased to 168 Mt at 0.59% NiS, 0.19% Cu
  • Completion of an underground PEA expected in Q3
  • Production on track to reach nominal annualised capacity in 2020

Atlantic Nickel (“Atlantic Nickel” or the “Company”) and Appian Capital Advisory LLP (“Appian”) are pleased to announce an update to both the operations and underground resource of the Santa Rita nickel sulphide mine (“Santa Rita” or the “Mine”) located in Bahia, Brazil.

Protecting our people and the community

As the COVID-19 pandemic unfolds, our priority remains the safety of our people and the communities in which we operate. Atlantic Nickel has adjusted working practices to protect employees: including enhanced screening, daily body temperature checks on every individual that enters the site, additional PPE equipment and hand sanitizer, and implementation of social distancing measures on the premises and on transport. In addition, we have been working alongside authorities to support the roll-out of robust mitigating actions in the communities in which we operate, including the acquisition of 6,000 units of rapid tests and a dedicated infrastructure to accommodate COVID-19 frontline health professionals. So far, these measures have been effective at limiting the spread of the virus though we continue to monitor their effectiveness to ensure our people and communities remain safe.

Operational update

Santa Rita remains fully operational despite the challenges caused by COVID-19. The Company has produced over 30,000 dry metric tonnes of nickel concentrate to date and is on target to ramp up to 105,000 tonnes by the end of 2020. The Brazilian government has declared mining an essential business activity and to date, there have been no material disruptions to our supply chains. Most of Atlantic Nickel’s suppliers and contractors are based in Brazil. Restrictions to travel have caused minor delays to the receipt of certain parts sourced internationally and some on-site collaboration with consultants based outside of Brazil, though altogether have had a limited impact on operations.

Appian has worked with Atlantic Nickel’s management team to resume production with a revised operating strategy and optimised processes. This has allowed a safe, capital efficient restart that has taken advantage of the existing infrastructure. Costs continue to decline as the operation ramps up. In the first quarter of 2020, C1 production costs were US$3.29/lb Ni net of by-products placing the Santa Rita in the first quartile of the industry cost curve.

Adapting to the challenges caused by COVID-19, Atlantic Nickel has been preparing and conducting virtual site visits to foster continued interaction and collaboration with external partners and counterparties. Parties interested in learning more can reach out to either Atlantic Nickel at comunicacao@atlanticnickel.com or Appian at info@appiancapitaladvisory.com.

Marketing update

Following the announcement of our first shipment of concentrate in January 2020, the Company has successfully completed its second and third shipments ahead of the mine’s original plan of commencing operations by the end of Q1 2020. Market demand for nickel sulphide concentrate has remained strong throughout the COVID-19 pandemic.

Resource update

A phased, comprehensive drilling programme that started in Q2 2019 has confirmed the exceptional upside potential of the mineral endowment, increasing Mineral Resources materially since the acquisition by Appian in 2018.

The updated Underground Mineral Resource estimate is shown in the table below, reflecting 167.8 Mt of total resources (Indicated + Inferred) grading 0.59% NiS, 0.19% Cu and 0.01% CoS. This resource is the continuation of the orebody and is defined immediately below the open pit resource of 59.1 Mt grading 0.31% NiS, 0.11% Cu and 0.01% CoS and has the potential to extend Santa Rita’s mine life to over 26 years. The Company is conducting additional drilling in 2020 intended to further grow and define the underground resource.




NiS (%)

Cu (%)

CoS (%)

Pd (ppm)

Pt (ppm)

Au (ppm)


















  • The Qualified Persons for the Mineral Resource Estimate are Timothy O. Kuhl, RM SME (MTS, formerly with Wood), Douglas Reid, P.Eng. (Wood) and Dr Ted Eggleston, RM SME (MTS).
  • Mineral Resources are reported within conceptual stope outlines constructed using Datamine MRO (Mineable Reserves Optimizer, minimum mineable unit 45 x 45 x 25 m, US$30/t NSR cut-off).
  • Mineral Resources are inclusive of Mineral Reserves.
  • Underground Mineral Resources are exclusive of open pit Mineral Resources.
  • Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.
  • Metal prices used for the Mineral Resource Estimate are: US$6.50/lb nickel, US$3.00/lb copper and US$20.00/lb cobalt.
  • Metal recoveries are: NiS=83%; Cu=70%; Co=29%.
  • Net Smelter Return (NSR) cut-off of US$30.00/t was used for the Mineral Resource Estimate.
  • Totals may not sum due to rounding.

Atlantic Nickel expects to complete a preliminary economic assessment for the underground expansion in Q3 2020 and looks forward to providing further details in due course.

Paulo Castellari, CEO Atlantic Nickel & Appian Brazil commented:

“COVID-19 is having a far-reaching impact on every country and industry sector. The health and safety of our people and local communities remains our foremost priority, and the decisive action we have taken during this difficult time has ensured our wellbeing while allowing continuity of operations.  

“Following Santa Rita’s re-start, I am delighted by the continued strong operational performance of the asset, which is testament to the ability of the Atlantic Nickel team, backed by Appian’s expertise and business model. Having returned the Mine to production ahead of plan, we continue to optimize costs and identify opportunities for operational improvements and further expansion. A sizable underground mineral resource has been defined and we look forward to announcing a preliminary economic assessment for its development later this year. I am very excited about our ability to consistently meet and exceed stakeholders’ expectations, which include our customers, suppliers, employees, communities and shareholders. Atlantic Nickel is now positioned as a low-cost, long-life operation with significant the potential for further expansion, and I look forward to providing updates on the PEA in due course.”

About Appian

Appian Capital Advisory LLP is the investment advisor to long-term value focused private equity funds that invest solely in mining and mining related companies.

Appian is a leading investment advisor in the metals and mining industry, with global experience across South America, North America, Australia and Africa and a successful track record of supporting companies and the advancement of their projects into production. Appian acquired Atlantic Nickel, the 100% owner of Santa Rita, in 2018.

About Atlantic Nickel

Atlantic Nickel is the owner and operator of Santa Rita, an open-pit nickel-copper-cobalt sulphide operation located in Bahia, Brazil. Santa Rita is a fully permitted, past-producing nickel mine currently undergoing an operational restart. The Mine benefits from US$1bn of prior investment and has an estimated production capacity of 6.5 Mtpa. One of the largest open pit nickel sulphide mines in the world, Santa Rita is a high-quality asset operating with a first quartile cost position. It is one of a few remaining nickel sulphide mines globally that can offer additional supply towards the production of Class I nickel products and so has exposure to the high-growth potential of the electric vehicle industry.

For further information:

Finsbury +44 (0)20 7251 3801
Charles O’Brien, Ruban Yogarajah, Richard Crowley

Appian Capital Advisory +44 (0)20 7004 0951
Michael Scherb, Adam Fisher

Related Links :


China Online Education Group Announces Proposed Follow-on Public Offering of American Depositary Shares

BEIJING, June 3, 2020 /PRNewswire/ — China Online Education Group (“51Talk” or the “Company”) (NYSE: COE), a leading online education platform in China, with core expertise in English education, today announced the commencement of a proposed registered underwritten public offering by the Company and certain selling shareholders of American depositary shares (the “ADSs”), each representing fifteen (15) Class A ordinary shares of the Company. The Company proposes to offer 428,571 ADSs (the “Primary ADS Offering”), and the selling shareholders propose to offer 1,000,000 ADSs (the “Secondary ADS Offering” and, together with the Primary ADS Offering, the “ADS Offering”). The underwriters in the ADS Offering will have a 30-day option to purchase up to 214,285 additional ADSs from the Company and certain selling shareholders solely for the purpose of covering overallotment.

Morgan Stanley & Co. LLC and Needham & Company, LLC are acting as the joint book-running managers for the ADS Offering.

The ADSs will be offered pursuant to the Company’s shelf registration statement on Form F-3 (the “Form F-3”), as amended, which was originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 6, 2020 and became effective on May 8, 2020. A preliminary prospectus supplement related to the proposed ADS Offering will be filed with the SEC. The Form F-3 and the preliminary prospectus supplement will be available at the SEC website at: http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained from (1) Morgan Stanley & Co. LLC, Prospectus Department, 2nd Floor, 180 Varick Street, New York, NY, 10014, United States of America, or by calling 1-866-718-1649, or by email at prospectus@morganstanley.com; (2) Needham & Company, LLC, Attention: Syndicate Prospectus Department, 250 Park Avenue, 10th Floor, New York, New York 10177, or by calling 800-903-3268, or by email at prospectus@needhamco.com.

This announcement shall not constitute an offer to sell, or a solicitation of an offer to buy, any securities, nor shall there be any offer, solicitation or sale of the securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

This press release contains information about the pending offering of the ADSs, and there can be no assurance that the offering will be completed.

About China Online Education Group

China Online Education Group (NYSE: COE) is a leading online education platform in China, with core expertise in English education. The Company’s mission is to make quality education accessible and affordable. The Company’s online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Company connects its students with a large pool of highly qualified foreign teachers that it assembled using a shared economy approach, and employs student and teacher feedback and data analytics to deliver a personalized learning experience to its students.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “aims”, “future”, “intends”, “plans”, “believes”, “estimates”, “likely to” and similar statements. 51Talk may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about 51Talk’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: 51Talk’s goals and strategies; 51Talk’s expectations regarding demand for and market acceptance of its brand and platform; 51Talk’s ability to retain and increase its student enrollment; 51Talk’s ability to offer new courses; 51Talk’s ability to engage, train and retain new teachers; 51Talk’s future business development, results of operations and financial condition; 51Talk’s ability to maintain and improve infrastructure necessary to operate its education platform; competition in the online education industry in China; the expected growth of, and trends in, the markets for 51Talk’s course offerings in China; relevant government policies and regulations relating to 51Talk’s corporate structure, business and industry; general economic and business conditions in China, the Philippines and elsewhere and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in 51Talk’s filings with the SEC. All information provided in this press release is as of the date of this press release, and 51Talk does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

China Online Education Group
Investor Relations
+86 (10) 8342-6262

The Piacente Group, Inc.
Brandi Piacente
+86 (10) 6508-0677
+1 (212) 481-2050

Hanafundme Launched COVID-19 Campaign to Help Supply PPE Items for Hospitals in Sabah

Hanafundme Launched COVID-19 Campaign to Help Supply PPE Items for Hospitals in Sabah

KUALA LUMPUR, Malaysia, June 2, 2020 /PRNewswire/ — Recently launched Women Crowdfunding platform, Hanafundme.com has embarked on a CSR fundraising campaign to supply PPE to the Hospital’s front liners in Sabah.

Hanafundme Launched COVID-19 Campaign to Help Supply PPE Items for Hospitals in Sabah
Hanafundme Launched COVID-19 Campaign to Help Supply PPE Items for Hospitals in Sabah

The said campaign that had taken place since March 2020 hopes to raise RM50,000 or more and has raised over RM22,000 to date, will be continued until end of the year to ensure that the supplies will be sufficient whenever there is a delayed supply due to logistic issues. Its first delivery will take place just after Raya this year and will comprise of disposable 3 ply masks and face shields. The platform hopes to raise more funds to meet its mission and to sustain the hospitals with the much needed supplies.

Through the Ministry Of Health’s logistic partner, supplies will be delivered via TUDM (Malaysia Air Force) directly to Queen Elizabeth Hospital (the main receiving hub for PPE supplies in Sabah) for their further distribution to other hospitals that are in need throughout Sabah.

According to Angie S Chin, the CEO & Co-Founder of Hanafundme.com, “We are aware that the MOH has also been supplying to the Hospitals in the state, however it’s been noted there have been times when the delivery of supplies have been delayed due to unforeseeable logistic issues. Hence the continuous supply of PPE to the front liners from those who can provide is necessary until the pandemic is under control.”

Being the first Women Crowdfunding platform in Malaysia, Hanafundme also hope to do their part by offering its platform to assist those affected by the pandemic by raising the necessary funds to stay afloat by encouraging small business owners, startups and freelancers to put up their campaigns on the platform.

Since the platform does not take any equity or offer loan money and unlike e-commerce platform that only sells products and services online, the platform allows the campaigners to share their story and reach out to their family, friends, customers and supporters to offer products or services in return of the funding support. Kind of like selling products and services in advance, where customers / supporters can redeem or receive the products or services later when the pandemic subsides.

To support this mission, the platform is currently open to all although initially it was created to support Girls or Women-owned start-ups, businesses, non-profits and side hustles raise funds to kick start or support innovative or impacting ideas, projects or missions by tapping on the Community’s support.

Hanafundme aspires to be one of the preferred women crowdfunding platform for enterprising and inspiring Women in Malaysia/ASEAN. The platform also supports the United Nation’s Sustainable Development Goals (SDG) to transform communities and the world, in particular the SDG pillars 5, 8, 9 and 10.

To keep up with the latest from Hanafundme, visit www.hanafundme.com or contact the hub at +603 2789 2470.  

Photo – https://photos.prnasia.com/prnh/20200601/2818302-1?lang=0

Related Links :


Innovent Announced the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study

SUZHOU, China, June 2, 2020 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic,  autoimmune and other major diseases, announced the preliminary results of the Phase 1a clinical study (NCT03875157) of the recombinant fully human anti-programmed bispecific antibody IBI318 against programmed death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) in patients with advanced tumors at the 56th American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract # 3062, Poster #126, 8:00 AM11:00 AM, U.S. Central Time, Friday, May 29, 2020).

The NCT03875157 study presented at the ASCO annual meeting was a Phase 1 clinical study conducted in China to evaluate the safety, tolerability and anti-tumor activity of IBI318 in subjects with advanced tumors. The main clinical data include:

  • As of January 10, 2020, a total of 15 subjects had enrolled in the 1a dose escalation phase, and the dose exploration phase of 600 mg Q2W is currently ongoing. A total of 11 subjects experienced treatment-related adverse events (TRAEs) and the most common TRAEs were pyrexia (20.0%, G1/2) and infusion reactions (20.0%, G1/2). There were no Grade 3 or higher TRAEs. One subject had a Grade 2 immune-related arthritis at a dose of 300 mg.
  • Twelve subjects had at least 1 tumor assessment, and 9 subjects received IBI318 treatment at doses of 10 mg and above, with 3 subjects experiencing an objective response.

Professor Ruihua Xu, the leader of the study and President of Zhongshan Cancer Prevention and Control Center, said: “Immunotherapy is entering into the era of bispecific antibodies from monoclonal antibodies. The preliminary results from NCT03875157 study show that IBI318, a first-in-class bispecific antibody, has an acceptable safety profile. We are hopeful to see positive results from the following studies to help more patients in need. “

About IBI318 (Anti-PD-1/PD-L1 Bispecific Antibody)

IBI318 is an innovative recombinant fully human IgG1 bispecific antibody that restores T cell activation and anti-tumor function by blocking PD-1 and PD-L1/PD-L2 signaling pathways, and blocking PD-L1 binding CD80 signaling pathway. IBI318 is expected to improve anti-tumor activity and efficacy by bridging PD-1-expressing T cells and PD-L1-expressing tumor cells through its bispecific ability to form an immune synapse between the two.

About Innovent

Inspired by the spirit of “Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of cancer, metabolic, autoimmune and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Since its inception, Innovent has developed a fully integrated multifunctional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 17 in clinical development, five in Phase 3 or pivotal clinical trials, four under NDA reviews by the NMPA (three under priority review status), while TYVYT® (sintilimab injection), officially approved for marketing in China in 2018, has been the only PD-1 inhibitor included in the NRDL, since 2019.

Innovent has built an international team of advanced talents in high-end biological drug development and commercialization, including many overseas experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners. Innovent strives to work with all relevant parties to help advance China’s biopharmaceutical industry, improve drug availability to ordinary people and enhance the quality of the patients’ lives. For more information, please visit:www.innoventbio.com.

Related Links :



Cellwize Lauded by Frost & Sullivan for its Cloud-based, AI open RAN automation platform, Chime

Cellwize’s automation platform successfully reduces the operator’s operating expenditure and the time-to-market of its 5G deployment and creates an open ecosystem for network deployments

SANTA CLARA, California, June 1, 2020 /PRNewswire/ — Based on its recent analysis of the global radio access network (RAN) automation market, Frost & Sullivan recognizes Cellwize with the 2020 Global Product Line Strategy Leadership Award for its Chime platform. Cellwize has pushed the envelope by engineering a solution that is easy to integrate into a multi-vendor RAN environment, and which enhances the level of automation and management.


“Cellwize has expanded its focus from optimizing the RAN to managing and automating the RAN itself, including implementing automation principles across the heterogeneous network and application layers. This vision resulted in the development of its flagship RAN management and automation platform, Cellwize Chime,” said Rohan Joy Thomas Industry Analyst. “Cellwize Chime utilizes AI and ML and is completely cloud-based and vendor-agnostic, has an open micro-services based architecture to address many key use cases, and is commercialized via flexible business models, including a pay-as-you-use model.”

Cellwize forges unique partnerships with other technology firms, which allows it to customize its go-to-market strategy according to the region. For instance, one of its notable partners, Tech Mahindra, is recognized for its technology consultancy expertise in the global telecommunications industry. Cellwize has leveraged this partnership to build its go-to-market strategies that are custom to the technological maturity of both the network operator and the region in which the network operator is located. Similarly, its partnership with Deloitte helps network operators with change management, which is essential during the deployment phase of the automation stack as well as throughout the value realization path.

Significantly, Cellwize Chime has enhanced Artificial intelligence  and machine learning capabilities, which change the information collected from external sources into a unified and open data model and exposes that data to Cellwize’s open application programming interfaces (APIs). It then passes the information to the operator’s many different applications that are deployed on the legacy Radio Access Technologies such as 2G, 3G, 4G, and the upcoming 5G deployment. On average, the platform helps network operators save 60 percent of their OPEX, which would have otherwise been spent on getting the RAN operational.

“Cellwize Chime moves from a static radio network policy to one that is adaptive through an enhanced AI/ML-type of governance, which provides carriers with significant flexibility to avoid vendor lock-ins, without going to their incumbent vendor for solutions,” noted Thomas. “In a multi-cloud environment that consists of edge compute and centralized clouds, Cellwize Chime can seamlessly integrate different components with each other across different environments.”

Each year, Frost & Sullivan presents this award to the company that has developed a comprehensive product line that caters to the breadth of the market it serves. The award recognizes the extent to which the product line meets customer base demands, and the overall impact it has in terms of customer value and increased market share.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.


Lindsey Whitaker
P: +1 (210) 477-8457
E: lindsey.whitaker@frost.com

About Cellwize

Cellwize is all about accelerating carriers’ 5G business through powerful mobile access automation, which will allow them to shorten TTM of their Next Gen Networks. Its cloud-native, AI-driven open platform enables mobile network operators (MNOs) to automate the configuration, management and optimization of networks and services; and with an advanced set of APIs, they can connect to any application and any vendor, as well as co-create on top of the platform. With Cellwize, MNOs gain unprecedented ease, speed and agility to accelerate the ROI on their network investments as well as time to market – even in the most complex and dynamic network environments, charging ahead with 5G, and always ready for the services and networks of tomorrow. Cellwize solutions are enabling the 5G journey for customers across North America, Latin America, Europe and APAC. For more information, visit www.cellwize.com.

Media Contact
Laura Raanan
GK for Cellwize

Related Links :


24 Exchange Expands its Board of Directors and Creates New Advisory Board

Tim Cartledge and Steven Resnick appointed as Directors; Jose Marques and Marty Pompadur appointed to Advisory Board

HAMILTON, Bermuda, June 1, 2020 /PRNewswire/ — 24 Exchange, a multi-asset class, 24-hour trading platform, announced today the appointment of Tim Cartledge and Steve Resnick to the 24 Exchange Board of Directors. These appointments increase the Board of Directors to five members. In addition, the company has created a Board of Advisors and appointed Jose Marques and Marty Pompadur as its first two members.

Dmitri Galinov, CEO and founder of 24 Exchange, said, “We are very excited to have both Tim and Steve join our exceptional Board of Directors. Tim is a recognized pioneer of the Foreign Exchange industry, with senior management roles at the top sell-side institutions and extensive work in electronic trading. The Board also will benefit from Steve’s incredibly deep understanding of financial markets and data analytics. We look forward to Steve and Tim both making an immediate positive impact as members of our Board.”

Tim Cartledge has held directorships at Broker Tec, NEX SEF and EBS, the primary trading venues for the U.S. Treasury and FX markets. He has more than 25 years of experience in financial markets specializing in both currency options market-making and electronic trading generally. Tim has held executive positions with Goldman Sachs, Credit Suisse, Dresdner Bank, and Barclays Bank, and most recently served as the Global Head of OTC FX Products at NEX/CME. He is best known for his work as architect of the Barclays BARX FX trading platform. Tim has a degree in Computer Science from Cambridge University.

Steve Resnick is the Founder and CIO of Navigator Capital Partners, a Fund of Funds, and is the Founder and President of Hedge IQ, a research and risk management consulting firm. He has 25 years of experience in the hedge fund industry following a two-decade career as a Wall Street analyst, portfolio strategist and director of research. He was formerly Chairman of the MIT Sloan Club of New York, and an adjunct professor of Baruch College. Steve holds a MS from MIT Sloan and a BA from the City University of New York.  

The 24 Exchange Advisory Board was established to provide additional outside expertise to the company’s management team and Board of Directors across a wide range of strategic and operational issues as 24 Exchange expands its global platform and service offerings.

Jose Marques has been named to the 24 Exchange Advisory Board. Jose brings more than 20 years of Wall Street experience, including as Founder and CIO of Inferent Capital. He also held senior trading positions at Bridgewater, Deutsche Bank, Credit Suisse, Hull Trading, and Morgan Stanley. Jose has a PhD from the University of California, Irvine.

Marty Pompadur has also been named to the Advisory Board. Marty has more than 50 years of experience as an executive in the Media industry. He has held a series of executive leadership positions at ABC Inc. including General Manager of Television Network, as well as senior management positions at News Corporation, including Chairman of News Corporation Europe. A former President of Ziff Corporation, Marty has a law degree from the University of Michigan Law School and a BA from Williams College.

Dmitri Galinov added, “Having Jose and Marty as the initial members of our Advisory Board has already been paying dividends due to their valuable insights and perspective. Both are respected leaders in their respective industries and experts in business strategy and relationship management.”

About 24 Exchange
24 Exchange is a multi-asset class, multi-dealer trading platform that allows market participants to exchange their exposures at the lowest possible cost. Our mission is to enable our members to initiate the most cost-effective trades across a growing range of asset classes, 24 hours a day. We lower the cost of exchanging assets in the global markets while delivering creative and unique workflows catered to each asset class. 24 Exchange is operated by 24 Exchange Bermuda Limited. The company is domiciled in Hamilton, Bermuda but is not regulated by the Bermuda Monetary Authority. More information is available at https://www.24exchange.net/.

Media Contact:

Eric Andrus
KARV Communications
Email: eca@karvcommunications.com
Phone: +1-212-333-0275

Related Links :


Proposed $25 Million Settlement Reached in Tezos Securities Litigation Pending in United States District Court for the Northern District of California

SAN FRANCISCO, June 1, 2020 /PRNewswire/ — This message has been authorized by Order of the United States District Court, Northern District of California in the matter In re Tezos Securities Litigation, No. 3:17-cv-06779-RS.

If you contributed money or cryptocurrency to the Tezos Foundation between July 1, 2017 and July 13, 2017, you may be entitled to share in a $25 million settlement.

Your rights will be affected by a class action lawsuit pending in the United States District Court, Northern District of California.

Pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the Northern District of California, the matter In re Tezos Securities Litigation, No. 3:17-cv-06779-RS (the “Action”) has been certified as a class action on behalf of a Settlement Class, except for certain persons and entities who are excluded from the Settlement Class by definition as set forth in the full Notice of Pendency of Class Action and Proposed Settlement; Settlement Fairness Hearing; and Motion for Award of Attorneys’ Fees and Reimbursement of Litigation Expenses (available at www.TezosFoundationSettlement.com) (the “Notice”).

Lead Plaintiff has reached a proposed settlement of the Action for $25,000,000 in cash (the “Settlement”) that, if approved, will resolve all claims in the Action.

A hearing will be held on August 27, 2020, at 1:30 p.m., before the Honorable Richard G. Seeborg at the United States District Court, Northern District of California, San Francisco Courthouse, Courtroom 3, 17th Floor, 450 Golden Gate Avenue, San Francisco, CA 94102, to determine (i) whether the Proposed Settlement should be approved as fair, reasonable, and adequate; (ii) whether the Action should be dismissed with prejudice against Defendants, and the Releases specified and described in the Stipulation and Agreement of Settlement dated March 16, 2020, should be granted; (iii) whether the proposed Plan of Allocation should be approved as fair and reasonable; and (iv) whether Federal and State Lead Counsel’s application for an award of attorneys’ fees and expenses should be approved.

If you are a member of the Settlement Class, your rights will be affected by the pending Action and the Settlement, and you may be entitled to share in the Settlement Fund. You should visit www.TezosFoundationSettlement.com to review the full Notice and download or fill out the Proof of Claim and Release Form (“Claim Form”). You may also obtain copies of the Notice and Claim Form by contacting the Claims Administrator at In re Tezos Securities Litigation, c/o Epiq, P.O. Box 3770, Portland, OR 97208-3770, 1-866-977-1042 or 1-503-597-7670.

The deadline to exclude yourself from the class or object is on August 6, 2020. The deadline to submit a claim is on October 16, 2020. You should carefully review the full notice on the Settlement Website at www.TezosFoundationSettlement.com.

Please do not contact the Court, the Clerk’s Office, the Tezos Foundation, or its counsel regarding this notice. All questions about the notice, the Proposed Settlement, or your eligibility to participate in the Settlement should be directed to Federal Lead Counsel or to the Claims Administrator.

Inquiries, other than requests for the Notice and Claim Form, should be made to Federal Co-Lead Counsel:

Block & Leviton LLP
260 Franklin Street, Suite 1860
Boston, MA 02110
(617) 398-5600

The Notice, Claim Form, and additional information can be found at www.TezosFoundationSettlement.com or by contacting the Claims Administrator at:

In re Tezos Securities Litigation
c/o Epiq
P.O. Box 3770
Portland, OR 97208-3770

U.S. & Canada Toll-Free Number: (866) 977-1042
International Number: (503) 597-7670
Email: info@TezosFoundationSettlement.com
Website: www.TezosFoundationSettlement.com

Related Links :